Review

mouse anti hcov229e spike antibody (Sino Biological)

Sino Biological is a verified supplier

Sino Biological manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Sino Biological mouse anti hcov229e spike antibody
Mouse Anti Hcov229e Spike Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hcov+229e/HCoV-229E+Spike+Antibody%2C+Mouse+MAb/pm42134697-72-24-31
Average 90 stars, based on 3 article reviews

mouse anti hcov229e spike antibody - by Bioz Stars, 2026-10

90/100 stars

Images

other:

Article Title: Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions.
Article Snippet: His-tagged full-length spike proteins SARS-CoV (Sino Biological, Cat#40634-V08B), SARS-CoV-2, MERS (Sino Biological, Cat#40069-V08B), HKU-1 (Sino Biological, Cat#40606-V08B), OC-43 (Sino Biological, Cat#40607-V08B), HCoV-229E (Sino Biological, Cat#40605-V08B) or S2 subunit SARS-CoV (Sino Biological, Cat#40150-V08B), SARS-CoV-2 (Sino Biological, Cat#40590-V08B), MERS (Sino Biological, Cat#40070-V08B), OC-43 or SARS-CoV-2 full-length prefusion stabilized trimer was loaded onto Ni-NTA biosensors (Sartorius ForteBio) until it achieved a 0.5–0.8 nm signal response or reached a maximum loading time of 800 s. The antigen loading time varied from 50 s to 800 s, resulting in 0.5–0.8 nm signal response depending on antigen (Fig. S10).

Article Title: Magnetic Bead-Based Electrochemical Surrogate Virus Neutralization Test for Quantification of Antibody Neutralizing Efficiency
Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article Title: Reimagining the serocatalytic model for infectious diseases: A case study of common coronaviruses.
Article Snippet: Of note, the S1 subunits of spike protein (His tag) of HCoV-229E (Seattle/USA/SC1073/2016), HCoV-HKU1 (Hong Kong/isolate N5/2006), HCoV-NL63 (Florida/UF-2/2015) and the hemagglutinin-esterase (HE) protein (His Tag) of HCoV-OC43 (Seattle/USA/SC9741/2016) were purchased from Sino Biological (China).

Article Title: Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions
Article Snippet: His-tagged full-length spike proteins SARS-CoV (Sino Biological, Cat#40634-V08B), SARS-CoV-2, MERS (Sino Biological, Cat#40069-V08B), HKU-1 (Sino Biological, Cat#40606-V08B), OC-43 (Sino Biological, Cat#40607-V08B), HCoV-229E (Sino Biological, Cat#40605-V08B) or S2 subunit SARS-CoV (Sino Biological, Cat#40150-V08B), SARS-CoV-2 (Sino Biological, Cat#40590-V08B), MERS (Sino Biological, Cat#40070-V08B), OC-43 or SARS-CoV-2 full-length prefusion stabilized trimer was loaded onto Ni-NTA biosensors (Sartorius ForteBio) until it achieved a 0.5–0.8 nm signal response or reached a maximum loading time of 800 s. The antigen loading time varied from 50 s to 800 s, resulting in 0.5–0.8 nm signal response depending on antigen ( ).

Article Title: Seasonal Coronavirus‐Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID
Article Snippet: The following antigens were used: SARS‐CoV‐2 spike protein (40589‐V08H4, Sino Biological), spike subunit 1 (S1) (100730, BPS Bioscience), spike subunit 2 (S2) (S2N‐C52H5, ACRO Biosystems), and nucleocapsid protein (40588‐V08B, Sino Biological), as well as the spike protein of HCoV‐OC43 (40607‐V08B), HCoV‐HKU1 (40606‐V08B), HCoV‐NL63 (40604‐V08B), and HCoV‐229E (40605‐V08B), and spike S2 of HCoV‐OC43 (40607‐V08B1) and HCoV‐HKU1 (40021‐V08B, all Sino Biological).

Article Title: Magnetic Bead-Based Electrochemical Surrogate Virus Neutralization Test for Quantification of Antibody Neutralizing Efficiency
Article Snippet: The potentially interfering antibodies included four human coronavirus (HCoV) spike polyclonal antibodies raised against HCoV-HKU1, HCoV-NL63, HCoV-229E, and HCoV-OC43 spike proteins (Cat. No. 40021-T62, 40600-T62, 40601-T62, and 40607-T62; SinoBiological).

Recombinant:

Article Title: Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan‐Coronavirus Inhibitor
Article Snippet: .. Recombinant Spike protein of SARS‐CoV‐2, HCoV‐229E, and HCoV‐OC43 were obtained from SinoBiological. ..

Image Search Results

(A): A549 clone 2E10 was treated with IFN⍺/IFNγ for 16h then infected as indicated. Infection was assessed 72 hpi by flow cytometry. (B): RNA-seq analysis heatmap depicting normalized expression of selected ISGs across four A549 SCCs (1B7, 1C10, 2E10, 3G7) after 16h mock/IFNα/IFNγ treatment. TPM; transcripts per million. (C): Venn diagram of overlap between differentially expressed genes (>4-fold change and padj < 0.05) following IFNα/IFNγ treatment. (D): Schematic of screen setup. (E): Screen results, where the x axis corresponds to each unique gene in the library, and the y axis denotes the relative fold change. Differentially represented genes in infected versus uninfected populations (p<0.01) are labeled in magenta, non-targeting controls are labeled in blue. (F): Flow cytometry of knockout cells treated with IFNα or IFNγ for 16h and infected with HCoV-OC43 for 72h (normalized to EV control).

Journal: bioRxiv

Article Title: Interferon-gamma induced RNF213 targets nascent double membrane vesicles to inhibit coronavirus primary translation

doi: 10.64898/2026.06.02.729663

Figure Lengend Snippet: (A): A549 clone 2E10 was treated with IFN⍺/IFNγ for 16h then infected as indicated. Infection was assessed 72 hpi by flow cytometry. (B): RNA-seq analysis heatmap depicting normalized expression of selected ISGs across four A549 SCCs (1B7, 1C10, 2E10, 3G7) after 16h mock/IFNα/IFNγ treatment. TPM; transcripts per million. (C): Venn diagram of overlap between differentially expressed genes (>4-fold change and padj < 0.05) following IFNα/IFNγ treatment. (D): Schematic of screen setup. (E): Screen results, where the x axis corresponds to each unique gene in the library, and the y axis denotes the relative fold change. Differentially represented genes in infected versus uninfected populations (p<0.01) are labeled in magenta, non-targeting controls are labeled in blue. (F): Flow cytometry of knockout cells treated with IFNα or IFNγ for 16h and infected with HCoV-OC43 for 72h (normalized to EV control).

Article Snippet: HCoV-OC43 (ATCC VR-1588) and HCoV-229E (ATCC VR-740) were obtained from Zeptometrix Corporation.

Techniques: Infection, Flow Cytometry, RNA Sequencing, Expressing, Labeling, Knock-Out, Control

(A): RNF213 KO (n=20) or EV (n=7) A549 SCCs were treated as indicated for 16h, infected with HCoV-OC43 at MOI 0.1 for 72h and percent infected cells determined by flow cytometry. Each dot represents an independent SCC (representative experiment, n=3; statistics used each clone as an data point, +/- SD, p values shown: student’s t-test). (B) : Growth curve of HCoV-OC43 in A549 EV or RNF213 KO cells pretreated, or not, for 16h with IFNγ and infected at MOI 0.1 (n=3). (C): Cells were pretreated with IFNγ for 16h and infected with HCoV-OC43 at MOI 5 for 24h. Labeled extracellular virions were run on an SDS-PAGE gel (representative image, n=3). (D): A549 cells were transfected with siRNAs against RNF213 or a non-targeting control (NT), pretreated with IFNγ for 16h, and plaque assay performed for rHCoV-OC43/eGFP (representative image, n=3, scale 1 mm). (E): Quantification of plaque size (representative experiment shown +/- SD, p values shown: 2-way ANOVA). (F): Quantification of plaque number (n=3, +/- SD, p values shown: 2-way ANOVA). (G): siRNA transfected A549 cells were pretreated or not with IFNγ and infected with HCoV-OC43. Percentage infected cells at 72 hpi was determined by flow cytometry (n=3 +/-SD), (H): Same as (G) , in Vero cells (I): Schematic of human RNF213 and locations of CRISPR-mediated editing. (J): Flow cytometry of A549 SCCs containing the indicated RNF213 mutations, pretreated with IFNγ (16h) and infected with HCoV-OC43 at MOI 0.1 for 72h. Each dot represents an independent SCC (representative experiment, n=3; statistics based on each clone as an independent experiment, +/- SD, p values shown: 2-way ANOVA). EV: empty vector. KO: knockout. MOI: multiplicity of infection. PFU: plaque forming units. Tri: Trimer. Mono: Monomer. SCC: single-cell clone.

Journal: bioRxiv

Article Title: Interferon-gamma induced RNF213 targets nascent double membrane vesicles to inhibit coronavirus primary translation

doi: 10.64898/2026.06.02.729663

Figure Lengend Snippet: (A): RNF213 KO (n=20) or EV (n=7) A549 SCCs were treated as indicated for 16h, infected with HCoV-OC43 at MOI 0.1 for 72h and percent infected cells determined by flow cytometry. Each dot represents an independent SCC (representative experiment, n=3; statistics used each clone as an data point, +/- SD, p values shown: student’s t-test). (B) : Growth curve of HCoV-OC43 in A549 EV or RNF213 KO cells pretreated, or not, for 16h with IFNγ and infected at MOI 0.1 (n=3). (C): Cells were pretreated with IFNγ for 16h and infected with HCoV-OC43 at MOI 5 for 24h. Labeled extracellular virions were run on an SDS-PAGE gel (representative image, n=3). (D): A549 cells were transfected with siRNAs against RNF213 or a non-targeting control (NT), pretreated with IFNγ for 16h, and plaque assay performed for rHCoV-OC43/eGFP (representative image, n=3, scale 1 mm). (E): Quantification of plaque size (representative experiment shown +/- SD, p values shown: 2-way ANOVA). (F): Quantification of plaque number (n=3, +/- SD, p values shown: 2-way ANOVA). (G): siRNA transfected A549 cells were pretreated or not with IFNγ and infected with HCoV-OC43. Percentage infected cells at 72 hpi was determined by flow cytometry (n=3 +/-SD), (H): Same as (G) , in Vero cells (I): Schematic of human RNF213 and locations of CRISPR-mediated editing. (J): Flow cytometry of A549 SCCs containing the indicated RNF213 mutations, pretreated with IFNγ (16h) and infected with HCoV-OC43 at MOI 0.1 for 72h. Each dot represents an independent SCC (representative experiment, n=3; statistics based on each clone as an independent experiment, +/- SD, p values shown: 2-way ANOVA). EV: empty vector. KO: knockout. MOI: multiplicity of infection. PFU: plaque forming units. Tri: Trimer. Mono: Monomer. SCC: single-cell clone.

Article Snippet: HCoV-OC43 (ATCC VR-1588) and HCoV-229E (ATCC VR-740) were obtained from Zeptometrix Corporation.

Techniques: Infection, Flow Cytometry, Labeling, SDS Page, Transfection, Control, Plaque Assay, CRISPR, Plasmid Preparation, Knock-Out, Single Cell

(A): Quantification of fluorescent signal for each of the indicated bands from (n=3, +/- SD, p-values displayed: student’s t-test). (B): Calculation of the ratio of each other protein to M (n=3, +/- SD, p-values displayed: student’s t-test). (C): Flow cytometry analysis of A549 RNF213 knock-out cells containing knock-in mutations in the guide RNA target sequence. Cells were pretreated for 16h with IFNγ and infected with HCoV-OC43 at MOI 0.1 for 72 hours (n=3, +/- SD, p-values shown: 2-way ANOVA). (D): Western blot of EV or RNF213 KO A549 cells pretreated with IFN for 24 hours (representative images shown, n=3). (E): Western blot of the indicated cells transfected with siRNAs against RNF213 or a non-targeting control, then pretreated with IFNγ for an additional 24 hours (representative images shown, n=3). (F-G): Flow cytometry of the indicated cells transfected with siRNAs, pretreated with IFNγ for 16 hours, and infected with HCoV-OC43 (F) or the indicated virus (G) at the indicated MOI for 72h, except VSV which was infected for 24h (n=3. +/- SD). (H): Western blot of A549 cells with the indicated point mutations pretreated with IFNγ for 24 hours (representative images shown, n=3).

Journal: bioRxiv

Article Title: Interferon-gamma induced RNF213 targets nascent double membrane vesicles to inhibit coronavirus primary translation

doi: 10.64898/2026.06.02.729663

Figure Lengend Snippet: (A): Quantification of fluorescent signal for each of the indicated bands from (n=3, +/- SD, p-values displayed: student’s t-test). (B): Calculation of the ratio of each other protein to M (n=3, +/- SD, p-values displayed: student’s t-test). (C): Flow cytometry analysis of A549 RNF213 knock-out cells containing knock-in mutations in the guide RNA target sequence. Cells were pretreated for 16h with IFNγ and infected with HCoV-OC43 at MOI 0.1 for 72 hours (n=3, +/- SD, p-values shown: 2-way ANOVA). (D): Western blot of EV or RNF213 KO A549 cells pretreated with IFN for 24 hours (representative images shown, n=3). (E): Western blot of the indicated cells transfected with siRNAs against RNF213 or a non-targeting control, then pretreated with IFNγ for an additional 24 hours (representative images shown, n=3). (F-G): Flow cytometry of the indicated cells transfected with siRNAs, pretreated with IFNγ for 16 hours, and infected with HCoV-OC43 (F) or the indicated virus (G) at the indicated MOI for 72h, except VSV which was infected for 24h (n=3. +/- SD). (H): Western blot of A549 cells with the indicated point mutations pretreated with IFNγ for 24 hours (representative images shown, n=3).

Article Snippet: HCoV-OC43 (ATCC VR-1588) and HCoV-229E (ATCC VR-740) were obtained from Zeptometrix Corporation.

Techniques: Flow Cytometry, Knock-Out, Knock-In, Sequencing, Infection, Western Blot, Transfection, Control, Virus

(A): Flow cytometry analysis of A549 cells transfected with siRNAs, treated with IFNγ for 16 hours, and infected with the indicated virus at the indicated MOI for 72h (n=3, +/- SD). (B): Same in Vero cells, except rHCoV-OC43/NLuc-NSP3/eGFP was infected for 48h. (C): Flow cytometry analysis of 293T cells infected with rHCoV-OC43/eGFP at MOI 0.1 for 72h, with normal human serum added at 4 hpi (representative experiment, n=3). (D): Same with A549 cells. (E): Flow cytometry analysis of Vero cells infected with rHCoV-OC43/eGFP at MOI 1 for 24h with soluble heparin added concurrently with infection. (F): Vero cells expressing LgBiT were infected with rHCoV-OC43/M-HiBiT at MOI 1 for 24h in the presence of the luciferase detection reagent endurazine. Soluble heparin was added at 0 hpi and/or at 24 hpi, and luminescence detected at 25 hpi (n=3. +/-SD). (G): qPCR of A549 cells infected with HCoV-OC43 at MOI 0.1 for 24h in the presence of Molnupiravir (representative images, n=3). (H): Western blot of EV or RNF213 KO A549 cells infected for the indicated time with HcoV-OC43 and 200 μM Molnupiravir (representative images, n=3.

Journal: bioRxiv

Article Title: Interferon-gamma induced RNF213 targets nascent double membrane vesicles to inhibit coronavirus primary translation

doi: 10.64898/2026.06.02.729663

Figure Lengend Snippet: (A): Flow cytometry analysis of A549 cells transfected with siRNAs, treated with IFNγ for 16 hours, and infected with the indicated virus at the indicated MOI for 72h (n=3, +/- SD). (B): Same in Vero cells, except rHCoV-OC43/NLuc-NSP3/eGFP was infected for 48h. (C): Flow cytometry analysis of 293T cells infected with rHCoV-OC43/eGFP at MOI 0.1 for 72h, with normal human serum added at 4 hpi (representative experiment, n=3). (D): Same with A549 cells. (E): Flow cytometry analysis of Vero cells infected with rHCoV-OC43/eGFP at MOI 1 for 24h with soluble heparin added concurrently with infection. (F): Vero cells expressing LgBiT were infected with rHCoV-OC43/M-HiBiT at MOI 1 for 24h in the presence of the luciferase detection reagent endurazine. Soluble heparin was added at 0 hpi and/or at 24 hpi, and luminescence detected at 25 hpi (n=3. +/-SD). (G): qPCR of A549 cells infected with HCoV-OC43 at MOI 0.1 for 24h in the presence of Molnupiravir (representative images, n=3). (H): Western blot of EV or RNF213 KO A549 cells infected for the indicated time with HcoV-OC43 and 200 μM Molnupiravir (representative images, n=3.

Article Snippet: HCoV-OC43 (ATCC VR-1588) and HCoV-229E (ATCC VR-740) were obtained from Zeptometrix Corporation.

Techniques: Flow Cytometry, Transfection, Infection, Virus, Expressing, Luciferase, Western Blot

Review

mouse anti hcov229e spike antibody (Sino Biological)

Structured Review

Images

Related Articles

other:

Recombinant:

Similar Products

Image Search Results